Overview of Glp 1 Drugs May Help Colon Cancer Patients Live Longer Study Finds

GLP-1 medications may help colon cancer patients live longer by reducing inflammation and improving metabolic health, UC San Diego researchers found in a 6,800- patient study .

The next logical step would be for doctors to test GLP-1s head-to-head against a sham placebo drug , to prove GLP-1s really do help colon cancer patients live longer .
Wegovy and Ozempic tied to dramatically lower cancer deaths

GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients , according to a major UC San Diego study . Patients on the medications had less than half the mortality rate of ...
A new University of California San Diego study offers compelling evidence that GLP-1 receptor agonists — the class of drugs behind Ozempic, Wegovy and Mounjaro, for example — may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 ...

Useful Notes on Glp 1 Drugs May Help Colon Cancer Patients Live Longer Study Finds
The survival benefit appeared most pronounced in patients with very high BMI (over 35), hinting that GLP-1 drugs may help counteract the inflammatory and metabolic conditions that worsen colon ...
Colon cancer is among the leading causes of cancer -related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting evidence. 1,2 A retrospective cohort study comparing the use of GLP-1 RAs in patients with colon ...

Overview of Glp 1 Drugs May Help Colon Cancer Patients Live Longer Study Finds
The study added to a recent accumulation of evidence regarding effects of the GLP-1 agonist class of diabetes/obesity drugs on cancer . One analysis showed a lower risk for 12 of 13 obesity-related ...
The 5-year survival prognosis of people with colon cancer who were also taking GLP-1 drugs was better than that of peers not on this medication, a new study shows.

Key Details About Glp 1 Drugs May Help Colon Cancer Patients Live Longer Study Finds
A real-world analysis of nearly 7000 patients shows GLP-1s are associated with sharply lower death rates at 5 years in patients with colon cancer with obesity.








Abstract Colorectal cancer is a leading cause of morbidity and mortality worldwide. This study investigates the association between GLP-1 receptor agonists ( GLP-1 RAs) and five-year mortality in patients with primary colon cancer , considering BMI. Using data from the University of California Health Data Warehouse, 6,871 patients were analyzed.